Adrian Jubb

2007-2011 University of Oxford, Oxford, United Kingdom 
"Adrian Jubb"
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Milani M, Venturini S, Bonardi S, et al. (2017) Hypoxia-related biological markers as predictors of epirubicin-based treatment responsiveness and resistance in locally advanced breast cancer. Oncotarget. 8: 78870-78881
Oon CE, Bridges E, Sheldon H, et al. (2017) Role of Delta-like 4 in Jagged1-induced tumour angiogenesis and tumour growth. Oncotarget
Mehta S, Hughes NP, Li S, et al. (2016) Radiogenomics Monitoring in Breast Cancer Identifies Metabolism and Immune Checkpoints as Early Actionable Mechanisms of Resistance to Anti-angiogenic Treatment. Ebiomedicine
Chen TT, Filvaroff E, Peng J, et al. (2015) MET Suppresses Epithelial VEGFR2 via Intracrine VEGF-induced Endoplasmic Reticulum-associated Degradation. Ebiomedicine. 2: 406-20
Ong CC, Gierke S, Pitt C, et al. (2015) Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents. Breast Cancer Research : Bcr. 17: 59
Zhou W, Jubb AM, Lyle K, et al. (2014) PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition. The Journal of Pathology. 234: 502-13
Oon CE, Bridges E, Sheldon H, et al. (2014) Functional comparison of Notch ligands in tumour angiogenesis Asian Pacific Journal of Tropical Disease. 4: 229
Blick C, Ramachandran A, Wigfield S, et al. (2013) Hypoxia regulates FGFR3 expression via HIF-1α and miR-100 and contributes to cell survival in non-muscle invasive bladder cancer. British Journal of Cancer. 109: 50-9
Brauer MJ, Zhuang G, Schmidt M, et al. (2013) Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 3681-92
Ong CC, Jubb AM, Jakubiak D, et al. (2013) P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma. Journal of the National Cancer Institute. 105: 606-7
See more...